Bronchiectasis is a chronic respiratory condition defined by abnormal widening of the bronchi, which results in mucus accumulation, persistent inflammation, and recurrent infections. Unlike other airway diseases, it is not limited to a single cause; it may arise following severe childhood infections, immune deficiencies, or genetic disorders such as cystic fibrosis, making it a condition with diverse clinical presentations. Individuals frequently experience ongoing cough, daily sputum production, and frequent exacerbations that contribute to progressive structural damage and a decline in lung function. For these reasons, bronchiectasis care must be comprehensive, long term, and adapted to the needs of each patient.
Central to effective management are airway clearance techniques, ranging from chest physiotherapy and oscillatory devices to newer high-frequency technologies designed to mobilize secretions. Antibiotic therapy, administered orally, intravenously, or through inhalation, is critical to treating acute infections and preventing recurrence, though careful attention is required to reduce resistance. Anti-inflammatory agents, bronchodilators, and in selected cases biologic therapies are increasingly explored to reduce airway inflammation. Emerging microbiome studies are shedding light on bacterial persistence and shaping new therapeutic strategies. Beyond pharmacological interventions, multidisciplinary teams—including pulmonologists, physiotherapists, nutritionists, and psychologists—play a vital role in sustaining adherence and improving outcomes. Education and empowerment of patients encourage active involvement in daily care, lowering exacerbation frequency. The modern approach to bronchiectasis care emphasizes proactive monitoring, individualized treatment, and long-term support, transforming what was once a neglected disease into a condition that can be managed effectively with coordinated clinical and patient-centered strategies.
Title : Novel signaling mechanisms and innovative therapeutic strategies of pulmonary hypertension
Yong Xiao Wang, Albany Medical College, United States
Title : Changing population immunity to COVID-19 in the context of infection, vaccination and emerging SARS-CoV-2 variants
Ranjan Ramasamy, ID-FISH Technology, United States
Title : Susceptibility to SARS-CoV-2 infection and nasal air conditioning ability
Ranjan Ramasamy, ID-FISH Technology, United States
Title : Comparative evaluation of DECAF and BAP 65 scores in predicting outcomes of COPD exacerbations among in patients at Vicente Sotto Memorial Medical Center
Allanys Joy Q Pino, Vicente Sotto Memorial Medical Center, Philippines
Title :
Saurabh Chattopadhyay, University of Kentucky College of Medicine, United States
Title : Personalized and precision Medicine (PPM) as a unique healthcare model through biodesign driven and inspired biotech, translational applications and pulmonology related marketing to secure the human healthcare, wellness and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation